Cargando…
The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation
BACKGROUND/AIM: This study aimed to evaluate the clinical efficacy of radiofrequency ablation (RFA) and cryotherapy and to scrutinize the therapeutic success of the RENAL (radius, exophytic/endophytic, nearness to collecting system, anterior/posterior, and location) nephrometry score in terms of pos...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018310/ https://www.ncbi.nlm.nih.gov/pubmed/31062941 http://dx.doi.org/10.3906/sag-1811-131 |
_version_ | 1783497328018063360 |
---|---|
author | ALADAĞ KURT, Seda YÜCEL, Cem ÖZHAN OKTAR, Suna ERBAŞ, Gonca SÖZEN, Sinan ÖNER, Ali Yusuf |
author_facet | ALADAĞ KURT, Seda YÜCEL, Cem ÖZHAN OKTAR, Suna ERBAŞ, Gonca SÖZEN, Sinan ÖNER, Ali Yusuf |
author_sort | ALADAĞ KURT, Seda |
collection | PubMed |
description | BACKGROUND/AIM: This study aimed to evaluate the clinical efficacy of radiofrequency ablation (RFA) and cryotherapy and to scrutinize the therapeutic success of the RENAL (radius, exophytic/endophytic, nearness to collecting system, anterior/posterior, and location) nephrometry score in terms of possible complications and the predictive status of oncological results. MATERIALS AND METHODS: Forty-five patients with biopsy-proven renal cell carcinomas (32 males, 13 females) treated with RFA and cryotherapy were included. Patients were 22–90 years old (average: 59.2 years). Statistical analyses were performed using SPSS for Windows. RESULTS: A total of 79 lesions with dimensions varying between 0.9 and 4.5 cm (average: 2.2 cm) were ablated. Complete ablation was achieved for 72 (91.1%) lesions. Six repeat RFA sessions were applied for 4 (5%) lesions with residue/recurrence. The average RENAL nephrometry scores of lesions that underwent complete ablation and those that developed residue/recurrence were 6.3 and 7.7, respectively. The average recurrence-free survival time was 34.8 months (range: 3–55 months), while it was 44.6 months (range: 6–55 months) for cryotherapy and 28.6 months (range: 3–50 months) for RFA. CONCLUSIONS: Ablative therapies are minimally invasive and effective methods for treating small renal tumors. RENAL nephrometry scoring is a valuable system for standardizing renal tumors and evaluating the success of ablative therapies, possible complications, and oncological results. |
format | Online Article Text |
id | pubmed-7018310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Scientific and Technological Research Council of Turkey |
record_format | MEDLINE/PubMed |
spelling | pubmed-70183102020-03-23 The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation ALADAĞ KURT, Seda YÜCEL, Cem ÖZHAN OKTAR, Suna ERBAŞ, Gonca SÖZEN, Sinan ÖNER, Ali Yusuf Turk J Med Sci Article BACKGROUND/AIM: This study aimed to evaluate the clinical efficacy of radiofrequency ablation (RFA) and cryotherapy and to scrutinize the therapeutic success of the RENAL (radius, exophytic/endophytic, nearness to collecting system, anterior/posterior, and location) nephrometry score in terms of possible complications and the predictive status of oncological results. MATERIALS AND METHODS: Forty-five patients with biopsy-proven renal cell carcinomas (32 males, 13 females) treated with RFA and cryotherapy were included. Patients were 22–90 years old (average: 59.2 years). Statistical analyses were performed using SPSS for Windows. RESULTS: A total of 79 lesions with dimensions varying between 0.9 and 4.5 cm (average: 2.2 cm) were ablated. Complete ablation was achieved for 72 (91.1%) lesions. Six repeat RFA sessions were applied for 4 (5%) lesions with residue/recurrence. The average RENAL nephrometry scores of lesions that underwent complete ablation and those that developed residue/recurrence were 6.3 and 7.7, respectively. The average recurrence-free survival time was 34.8 months (range: 3–55 months), while it was 44.6 months (range: 6–55 months) for cryotherapy and 28.6 months (range: 3–50 months) for RFA. CONCLUSIONS: Ablative therapies are minimally invasive and effective methods for treating small renal tumors. RENAL nephrometry scoring is a valuable system for standardizing renal tumors and evaluating the success of ablative therapies, possible complications, and oncological results. The Scientific and Technological Research Council of Turkey 2019-06-18 /pmc/articles/PMC7018310/ /pubmed/31062941 http://dx.doi.org/10.3906/sag-1811-131 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article ALADAĞ KURT, Seda YÜCEL, Cem ÖZHAN OKTAR, Suna ERBAŞ, Gonca SÖZEN, Sinan ÖNER, Ali Yusuf The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title | The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title_full | The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title_fullStr | The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title_full_unstemmed | The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title_short | The effectiveness of RENAL nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
title_sort | effectiveness of renal nephrometry score in ablated renal tumors via radiofrequency ablation or cryoablation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018310/ https://www.ncbi.nlm.nih.gov/pubmed/31062941 http://dx.doi.org/10.3906/sag-1811-131 |
work_keys_str_mv | AT aladagkurtseda theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT yucelcem theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT ozhanoktarsuna theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT erbasgonca theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT sozensinan theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT oneraliyusuf theeffectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT aladagkurtseda effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT yucelcem effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT ozhanoktarsuna effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT erbasgonca effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT sozensinan effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation AT oneraliyusuf effectivenessofrenalnephrometryscoreinablatedrenaltumorsviaradiofrequencyablationorcryoablation |